Group 1 - The company, Aikang Medical, announced that its wholly-owned subsidiary, Beijing Yidian Lingdong Technology Co., Ltd., successfully won the bid for the orthopedic hip joint surgery navigation system project at Zhejiang University School of Medicine First Affiliated Hospital [1] - The K3 intelligent surgical robot system, developed entirely in-house, is designed to be compact and efficient, providing functionalities from preoperative planning to intraoperative assistance, aiming to enhance surgical precision and efficiency [1] - The K3+ robot system received approval from the National Medical Products Administration on January 15, 2026, making it the first all-joint surgical robot in China capable of performing revision surgeries, covering hip, knee, and unicompartmental indications [1] Group 2 - The Visual Treatment Solution (VTS system) integrates medical-engineering interaction for preoperative planning and real-time monitoring, aimed at improving the surgical performance and clinical efficacy of total hip arthroplasty [1] - The company is actively promoting digital orthopedic construction, utilizing smart technology to enhance the diagnostic and treatment levels of medical institutions [2] - The digital orthopedic solutions offered by the company encompass a full range of services, including 3D modeling, surgical planning, 3D model printing, customized surgical tools, and customized prosthetics [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限責任公司） (股份代號：1789) 自願性公告 業務更新 本公告由愛康醫療控股有限公司（「本公司」，連同其附屬公司稱為「本集團」）自願 作出，以向本公司股東（「股東」）及潛在投資者提供有關本集團最新業務發展的最 新資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司全資附屬公司北京壹點靈 動科技有限公司近日成功中標浙江大學醫學院附屬第一醫院骨科髖關節手術導 航系統等設備項目。此外，於2024年12月至2026年1月期間，本集團獲得多項中 標，中標概要載列如下： | | 中標結果╱ | | | --- | --- | --- | | 招標者 | 簽約日期 | 中標公告價格 （人民幣元） | | • 山東省立醫院 | 2024年12月 | （附註） 446萬 | | • 青島市中醫醫院（市海慈醫院） | 2025年08月 | 680 萬 | | • 北京大學第三醫院 | ...

港通医疗2025年三季报显示，前三季度公司主营收入3.44亿元，同比下降30.06%；归母净利润-1020.84 万元，同比下降150.92%；扣非净利润-1286.52万元，同比下降176.82%；其中2025年第三季度，公司单 季度主营收入7911.64万元，同比上升42.81%；单季度归母净利润-180.4万元，同比下降138.94%；单季 度扣非净利润-259.58万元，同比下降182.34%；负债率40.94%，投资收益-17.94万元，财务费用54.24万 元，毛利率22.45%。港通医疗（301515）主营业务：医用气体装备及系统、医用洁净装备及系统的研 发、设计、制造、集成及运维服务。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 证券之星消息，截至2026年2月9日收盘 ...

Group 1 - The core viewpoint of the news is that Wuzhou Medical (301234) has shown a slight increase in stock price, with a closing price of 41.9 yuan on February 9, 2026, reflecting a 1.4% rise [1] - The company reported a main revenue of 345 million yuan for the first three quarters of 2025, representing a year-on-year increase of 0.82% [2] - The net profit attributable to the parent company for the same period was 18.51 million yuan, showing a significant year-on-year decline of 46.09% [2] Group 2 - In the third quarter of 2025, the company's single-quarter main revenue was 128 million yuan, which is a year-on-year decrease of 1.51% [2] - The net profit attributable to the parent company for the third quarter was 7.99 million yuan, down 36.39% year-on-year [2] - The company's debt ratio stands at 12.32%, with an investment income of 3.67 million yuan and a financial expense of -2.07 million yuan [2] Group 3 - The company operates in the field of research, production, and sales of disposable sterile infusion medical devices, primarily using an "ODM + integrated supply" model to meet the one-stop procurement needs of foreign medical device brand owners [2] - The gross profit margin for the company is reported at 14.22% [2] Group 4 - On February 9, 2026, the net inflow of main funds was 762,700 yuan, accounting for 2.21% of the total transaction amount [1] - Retail investors saw a net inflow of 1.40 million yuan, representing 4.06% of the total transaction amount, while speculative funds experienced a net outflow of 2.17 million yuan, which is 6.27% of the total transaction amount [1]

Group 1 - Huatai Medical plans to repurchase shares worth between 150 million to 200 million yuan for employee stock ownership plans or equity incentives, with a repurchase price not exceeding 315 yuan per share [1][3] - Aopt plans to raise no more than 1.38 billion yuan for projects related to AI intelligent vision solutions and industrial 3D vision sensors [1][4] - Weimais reported a net profit of 557 million yuan for 2025, a year-on-year increase of 39.22%, despite a slight decline in total revenue [1][6] Group 2 - Jiaokong Technology signed a contract for the Sydney Metro West Line TSMO signal system subcontract project, with a contract value of approximately 93.53 million Australian dollars [1][5] - Microelectrophysiology received EU MDR certification for its magnetic navigation ablation catheter and star-shaped high-density mapping catheter, facilitating entry into the European market [1][4] - Firmus Technologies, an Australian AI infrastructure company, secured 10 billion USD in debt financing led by Blackstone for data center expansion [8][9]

惠泰医疗(688617.SH)发布公告，公司拟1.5亿元至2亿元回购股份，回购股份价格不超过315元/股，回购 的股份将在未来适宜时机用于员工持股计划或股权激励。 ...

Core Viewpoint - The stock of Kaili Medical (300633) has shown a slight increase in price, with recent trading data indicating mixed capital flows among different investor categories [1][2]. Group 1: Stock Performance and Trading Data - As of February 9, 2026, Kaili Medical's stock closed at 27.39 yuan, up by 0.88%, with a turnover rate of 0.52% and a trading volume of 22,400 lots, amounting to 61.21 million yuan [1]. - On February 9, the net inflow of main funds was 2.21 million yuan, accounting for 3.61% of the total trading volume, while retail investors experienced a net outflow of 4.74 million yuan, representing 7.74% of the total [1]. - Over the past five days, the stock has seen fluctuations in capital flows, with notable net inflows and outflows from different investor categories [1]. Group 2: Company Financial Metrics and Industry Comparison - Kaili Medical's total market capitalization is 11.85 billion yuan, which is above the industry average of 11.08 billion yuan, ranking 30th out of 129 companies in the medical device sector [2]. - The company reported a net profit of 33.51 million yuan, significantly lower than the industry average of 207 million yuan, ranking 77th in the industry [2]. - The company's price-to-earnings ratio stands at 265.26, which is considerably higher than the industry average of 89.2, ranking 91st [2]. - Kaili Medical's gross margin is 60.36%, which exceeds the industry average of 50.16%, ranking 51st [2]. - The company reported a debt ratio of 24.22% and a return on equity (ROE) of 1.07%, which is higher than the industry average of 0.41%, ranking 87th [2]. Group 3: Analyst Ratings - In the last 90 days, five institutions have provided ratings for Kaili Medical, with four giving a "buy" rating and one an "accumulate" rating [3].

Core Viewpoint - Bluefan Medical (002382) has reported a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations [2]. Financial Performance - For the first three quarters of 2025, Bluefan Medical's main revenue was 4.182 billion yuan, a year-on-year decrease of 10.15% [2]. - The net profit attributable to shareholders was -286 million yuan, down 30.09% year-on-year [2]. - The net profit excluding non-recurring items was -364 million yuan, reflecting a decline of 46.25% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 1.401 billion yuan, a decrease of 15.02% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -151 million yuan, a significant drop of 153.64% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was -155 million yuan, down 151.16% year-on-year [2]. - The company's debt ratio stood at 41.01% [2]. - Investment income was reported at 13.482 million yuan, while financial expenses amounted to 140 million yuan [2]. - The gross profit margin was 13.66% [2]. Market Activity - As of February 9, 2026, Bluefan Medical's stock closed at 6.02 yuan, with an increase of 0.84% [1]. - The turnover rate was 0.95%, with a trading volume of 94,600 hands and a transaction value of 56.912 million yuan [1]. - On February 9, the net inflow of main funds was 1.728 million yuan, accounting for 3.04% of the total transaction value [1]. - The net inflow of speculative funds was 1.7175 million yuan, representing 3.02% of the total transaction value [1]. - Retail investors experienced a net outflow of 3.4455 million yuan, which was 6.05% of the total transaction value [1].

截至收盘，科创200指数上涨3.2%，科创100指数上涨2.8%，科创成长指数上涨2.7%，科创50指数、科创综指均上涨2.5%。Wind数据显示，科创60ETF 易方达（588080）上周连续5个交易日获资金净流入，合计近10亿元。 令日 该指数涨跌 2. 8% 该指数 滚动市盈率 2023年 207.8倍 发 科创板系列指数基本情况跟踪 (2026年2月9日) 科创50ETF易方达 低费率 跟踪上证科创板50成份指数 | 该指数由科创板中市值大、流动性 | 令日 | 该指数 | 该指数自 | | --- | --- | --- | --- | | 好的50只股票组成, "硬科技"龙 | 该指数涨跌 | 滚动市盈率 | 发布以来 | | 头特征显著,半导体占比超65%, | | | | | 与医疗器械、软件开发、光伏设备 | 2. 5% | 162.4倍 | 94. | | 行业合计占比近80% | | | | 科创100ETF易方达 【股票送3 跟踪上证科创板100指数 该指数由科创板中市值中等且流动 性较好的100只股票组成,聚焦中 小科创企业,电子、电力设备、医 药生物、计算机行业合计占比超 75%, ...

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15] - The implementation plan for the high-quality development of the TCM industry (2026-2030) aims to establish a collaborative development system for the entire industry chain by 2030, fostering leading TCM enterprises and promoting the approval of innovative TCM drugs [4][15] - The report identifies specific companies that are expected to benefit from these policies, including Yiling Pharmaceutical, Tianshili, Kangyuan Pharmaceutical, and Fangsheng Pharmaceutical [5][16][17] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a 52-week high of 9323.49 and a low of 6876.88 [1] Recent Market Performance - During the week of February 2 to February 6, 2026, the A-share pharmaceutical and biotechnology sector rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points and the ChiNext index by 3.43 percentage points [6][18] - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline of 2.42% [18] Investment Recommendations 1. **Innovative Drugs**: The innovative drug sector is expected to continue to be a strong growth area, with a focus on companies with high certainty and relatively low business development (BD) expectation disturbances, such as Innovent Biologics, Sanofi, and others [7][21] 2. **Medical Devices**: The medical device sector is showing signs of recovery, with leading companies improving their performance in Q3. The report suggests that the pressure from centralized procurement is diminishing, which may lead to valuation recovery [8][23] 3. **Traditional Chinese Medicine**: The report is optimistic about TCM companies benefiting from centralized procurement and basic drug policies, with specific companies highlighted for their potential growth [29][30] 4. **AI in Healthcare**: Companies leveraging AI technology in drug development and medical services are expected to see significant benefits, with specific companies listed for each AI application area [9][32][34]